Jinhai Medical Technology Limited Overview
Jinhai Medical Technology is a small-cap, Hong Kong-listed holding company in the late stage of a pivot from a Singapore construction-labour supplier into a Shanghai-based distributor and solutions provider of minimally invasive surgery (MIS) products. The legacy business, founded in 2006 as Kakiko, supplies foreign construction workers, operates workers' dormitories and provides small IT and construction-ancillary services in Singapore. Since Shanghai real-estate entrepreneur Chen Guobao acquired control in 2019, the group has built a PRC medical-device business that grew from S$0.7 million of revenue in FY2022 to S$30.0 million in FY2025 and S$25.4 million in 1H2026 alone, now 75% of group revenue. Its most visible technology claim is a navigated spinal endoscopy technique co-launched with Medtronic China in late 2025. The group remains loss-making, highly customer-concentrated and thinly margined, yet trades at a market value of roughly HK$22.5 billion, more than 50 times trailing sales.
What the company does
The group reports two operating "natures" plus a corporate cost centre. The CODM (the executive directors) reviews revenue by nature and profit or loss for the group as a whole, so the group presents only entity-wide IFRS 8 disclosures: "Products", "Services" and "Others" (FY2025 results, Note 3).
-
Products (PRC): provision of minimally invasive surgery solutions and medical products and the related service fee. Revenue is recognised at a point in time. It is earned through Shanghai Jinhai Medical Technology Company Limited (上海今海醫療科技有限公司) and related PRC subsidiaries, including Jinhai Technology Development (Shanghai) Co., Ltd. and, from January 2026, the 51%-owned Jinhai Biomedical Technology (Shanghai) Co., Ltd.
-
Services (mainly Singapore): manpower outsourcing and ancillary services to building and construction contractors; workers' dormitory services, accounted for as rental income; IT services (historically to a single customer); and construction ancillary services (warehousing, cleaning and building maintenance). The 2025 Annual Report's Report of the Directors also mentions manpower outsourcing in China, and the FY2025 geographic split shows a small amount of PRC service revenue, but this is immaterial.
-
Others: corporate office functions (Hong Kong and holding-company costs, including the large equity-settled share-based payment charges since 2024).
The company's own description (paraphrased from the latest filings)
In the 2025 Annual Report, management says it has reassessed strategic direction and resolved to allocate group resources to MIS solutions, medical products and related services. It frames China's MIS-device market as among the fastest growing globally. The company states it will compete by (a) strengthening R&D, (b) expanding its distribution network, (c) developing new products and (d) promoting resource integration. In the same report, management expects the Singapore labour-dispatch, dormitory and construction-related businesses to be materially affected as the Singapore Government reorients investment priorities from infrastructure towards AI. In the 1H2026 interim announcement it says it will review the market position and prospects of the Singapore manpower business in 2H2026.
Revenue model and mix
| Revenue type (FY2025) | Recognition | SGD K | % of total |
|---|---|---|---|
| Product sales: MIS solutions and medical products and related service fee (PRC) | Point in time | 29,964 | 64.7 |
| Service: manpower outsourcing and ancillary services | Over time | 12,685 | 27.4 |
| Rental: dormitory services (Singapore) | Lease income | 2,923 | 6.3 |
| Service: IT services | Over time | 434 | 0.9 |
| Service: construction ancillary services | Over time | 270 | 0.6 |
| Total | — | 46,276 | 100.0 |
Source: FY2025 annual results announcement, Note 3 and MD&A.
In 1H2026 the product line rose to S$25.4 million of S$34.0 million (74.7%). The model is therefore now predominantly product sales, with no disclosed subscription or licensing revenue. The product revenue line includes a "related service fee", but the split between hardware/consumable sales and service fees is not publicly disclosed.
Value-chain position: independent characterisation
The financial signature of the medical business points to a distribution and commercialisation model rather than a vertically integrated manufacturer:
Thin product margins: "Cost of inventories sold" relative to product revenue implies low gross margins: about 5.1% in FY2023 (19,390 vs 20,431), 4.5% in FY2024 (24,768 vs 25,927), 12.7% in FY2025 (26,162 vs 29,964) and 15.4% in 1H2026 (21,519 vs 25,427). This is an analyst approximation; inventory cost may not equal the full cost of product sales.
Minimal R&D: R&D expenditure was only S$850k in FY2024, S$742k in FY2025 and S$112k in 1H2026, against product revenue in the tens of millions.
Extreme customer concentration: In FY2024 a single customer ("Customer B") contributed S$24.2 million, 93% of product revenue. In 1H2026 two customers contributed S$25.0 million, 98% of product revenue. These patterns are consistent with sales to a small number of distributors or platform partners rather than to many hospitals directly.
Commercial build-out: A Chief Marketing Officer (Mr. Ma Chengdong) was appointed on 3 August 2026, with responsibility for marketing strategy, market access, academic promotion, sales and channel operations, and the commercialisation of the group's medical device and equipment products (voluntary announcement, 3 August 2026).
Technology partnership with Medtronic: In November 2025 the subsidiary co-launched a navigated spinal endoscope technique with Medtronic China's Orthopedics and Neurosurgery Business Group. On 6 November 2025 Jinhai Technology Development (Shanghai) signed a strategic cooperation framework agreement with Medtronic Changzhou Medical Device Co., Ltd. to promote real-time navigation and tracking spinal endoscopy in Chinese clinical practice (AR2025, Chairman's Statement). This positions Jinhai as a clinical-technique and channel partner adjacent to a global OEM.
In the Singapore legacy business, Jinhai is a labour intermediary (deploying foreign workers to contractors, paid by deployment hours, with salespeople commissioned on hours deployed) and a landlord of purpose-built workers' accommodation. Those properties are now pledged as security for group borrowings.
Customer types and end-markets
| Business | Customer type | End-market |
|---|---|---|
| MIS solutions and medical products | Not named. Two customers (A and B) accounted for 55.3% of group revenue in FY2025 and 73.6% in 1H2026 | PRC hospital surgical market (spine and broader MIS); end-users are surgeons and hospitals |
| Manpower outsourcing | Building and construction contractors in Singapore | Singapore construction |
| Dormitory services | Employers of foreign workers | Singapore foreign-worker accommodation |
| IT services | Historically a sole IT customer (FY2022 and FY2023 MD&A) | — |
| Construction ancillary | Contractors and industrial tenants | Singapore construction and industrial property |
Strategy
Stated strategy (themes from AR2025 and the 1H2026 interim)
-
Medical focus. Resources are to be allocated to MIS solutions, medical products and related services, which the board sees as the long-term growth driver.
-
Four competitive levers. (a) R&D capability, (b) distribution-network expansion, (c) new product development, (d) resource integration.
-
Healthcare M&A. Net proceeds of the August 2025 subscription are earmarked HK$96.6m for M&A of healthcare projects or companies and investment in healthcare industries, HK$32.2m for R&D and HK$32.2m for working capital, all targeted for use by December 2026.
-
Singapore review. Management expects the Singapore construction-linked businesses to be materially affected by the government's pivot to AI. The board will review the manpower business's market position in 2H2026, and the remaining HK$1.9m of IPO proceeds for lorries keeps being deferred.
-
Asia-Pacific expansion. A long-standing aim to extend existing businesses into the Asia-Pacific region, including China, and to add value-added labour services (skills training, quality improvement).
-
Cost discipline. Management is preserving cash through stricter cost controls amid geopolitical, trade-war and oil-crisis risks flagged for 2026.
Strategic initiatives in the last 24 months
| Date | Initiative | Type | Detail / target | Source |
|---|---|---|---|---|
| Jan 2024 | Singapore dormitory acquisition | Asset investment | S$10.2m | FY2023 results |
| 9 Jan 2024 | Performance-linked option grant to medical leadership | Talent / incentive | 128.6m pre-split options at HK$2.54 (514.4m post-split at HK$0.635), vesting 20/30/50% on 30 Apr 2025, 2026 and 2027 subject to performance targets | FY2025 results |
| 12 Dec 2024 | 1:4 share subdivision | Capital markets | To improve trading liquidity (rationale per circular of 22 Nov 2024) | FY2025 results |
| Aug 2025 | HK$162m equity raise from the Li family | Funding | Healthcare M&A, R&D, working capital | FY2025 results |
| Sep 2025 | Re-hiring of CFO Wong Man Yiu | Leadership | Finance, tax, treasury, IR, corporate finance | MarketScreener |
| Nov 2025 | Navigated spinal endoscopy launch with Medtronic China (CIIE) | Product / partnership | Spine surgery precision and adoption | AR2025 |
| 6 Nov 2025 | Medtronic Changzhou strategic cooperation framework | Partnership | Promote real-time navigation and tracking spinal endoscopy in Chinese clinical practice | AR2025 |
| 23 Jan / 25 Feb 2026 | Jinhai Biomedical JV and RMB20m capital increase | New business | Medical products; 51:49 with Li family vehicle | FY2025 results |
| 3 Aug 2026 | CMO appointment | Commercial build-out | Market access, academic promotion, channels | Announcement |
| 1H2026 | Capital project prepayments | Capex | S$2.85m PPE prepayment and S$3.6m prepayment to contractor (purpose not disclosed) | 1H2026 results |
ESG commitments. The group operates an environmental management system focused on electricity and water conservation, and reports no environmental non-compliance in FY2025 (AR2025 Directors' Report). It has published no quantitative emissions targets.
Medium-term financial targets or guidance. None publicly disclosed. Management offers only qualitative expectations, for example that medical sales will continue to grow in 2H2026.
Products & Services
The company publishes very little product-level detail in its HKEX filings. The catalogue below lists everything disclosed. Specifications, pricing and SKUs not stated in filings are marked accordingly.
Products segment (PRC)
| Offering | Description | Key specs/capabilities | Target customer | Launch/version | Pricing model | Source |
|---|---|---|---|---|---|---|
| Minimally invasive surgery solutions | Integrated MIS solution sales with a related service fee | — | PRC hospitals, via a small number of large customers | Business started 2019; material revenue from FY2023 | Point-in-time product sale plus related service fee; price points not disclosed | FY2023 and FY2025 results |
| Medical products / medical equipment | Sale of medical equipment and consumables (management uses "medical equipment" and "medical products" interchangeably) | — | PRC healthcare providers and distributors | 2019 onward | — | FY2025 MD&A |
| Navigated (real-time navigation and tracking) spinal endoscopy technique | Technique jointly launched with Medtronic China's Orthopedics & Neurosurgery Business Group at the 8th CIIE, November 2025; intended for spine surgery | Management says it should improve precision and intelligence in spinal surgery, shorten clinicians' learning curve for spinal endoscopy, and broaden clinical application. Device-level specifications and regulatory registration status not disclosed | Spine surgeons and hospitals in China | Launched Nov 2025; framework agreement with Medtronic Changzhou, 6 Nov 2025 | — | AR2025 Chairman's Statement |
| Jinhai Biomedical product platform | New 51%-owned subsidiary focused on medical products; registered capital RMB25m after Feb 2026 increase | Product scope not disclosed | — | Established 23 Jan 2026 | — | FY2025 results; 1H2026 results |
Flagship brands, trademarks or NMPA product registrations are not publicly disclosed in the filings reviewed. The co-chairman's background as founder of Shanghai Anbaida (in-vitro diagnostic reagent sales) and as a first-tier distributor of Roche Diagnostics in Shanghai since 2004 suggests IVD distribution could become a future adjacency. This is an analyst inference and is not stated in company guidance.
Services segment (Singapore)
| Offering | Description | Specs/capabilities | Target customer | Since | Pricing model | Source |
|---|---|---|---|---|---|---|
| Manpower outsourcing and ancillary services | Deployment of foreign construction workers to contractors' projects, with ancillary services | Workforce of several hundred including foreign workers (472 total group employees at 30 Jun 2026); foreign worker levy S$2.9m in FY2025 | Building and construction contractors | 2,006 | Revenue recognised over time; sales commissions tied to hours of deployment, implying hourly or deployment-based billing | FY2025 results |
| Dormitory services | Workers' dormitories; investment properties carried at S$18.2m (30 Jun 2026), pledged for borrowings | One dormitory acquired Jan 2024 (S$10.2m); one ceased operation Oct 2024. Total bed count not disclosed | Employers of foreign workers | Pre-IPO | Rental income (IFRS 16) | FY2023 and FY2025 results |
| IT services | Maintenance and support days for a sole IT customer | — | Single customer | Pre-2021 | Over-time service fee by support days | FY2022 and FY2023 MD&A |
| Construction ancillary services | Warehousing, cleaning, building maintenance | Warehousing revenue fell with less industrial space rented out | Contractors and industrial occupiers | Pre-IPO | Over time | FY2022 and FY2023 MD&A |
| Value-added labour services (proposed) | Skills training and quality improvement for labour forces | Proposal only | Contractors | Not launched | — | AR2025 |
Financial Narrative
Methodology: EBIT is defined as profit before tax plus finance costs. EBITDA is EBIT plus depreciation of PPE, right-of-use assets and investment properties. Net income is "profit/(loss) for the year" (total); "attributable" is to owners of the company. Ratios are analyst calculations from filed figures.
Income statement: notes and sources
Sources: FY2022 results (FY2021 restated, FY2022); FY2023 results; FY2025 results (FY2024, FY2025). FY2021–FY2023 share-based payment shown as 0 because the option scheme was adopted only on 29 December 2023. Aggregator check: TipRanks EBITDA matches for FY2021–FY2023 (S$5.44m, S$5.25m, S$1.11m) but shows S$-16.82m for FY2024 against the -12.44m computed here, a definitional discrepancy that is noted.
Margins and growth
Revenue CAGR FY2021–FY2025: approx. 20.6% per year (21.9m to 46.3m). FY2021 YoY growth is against FY2020 revenue of S$22.47m (TipRanks; the restated basis may differ). Longer-run context from TipRanks (aggregator): revenue was S$45.05m (FY2016), S$44.44m (FY2017), S$47.46m (FY2018) and S$51.90m (FY2019) before falling to S$22.47m in FY2020 during Singapore's COVID-19 dormitory lockdowns and construction stoppage. On this longer view, FY2025 group revenue is still below pre-pandemic levels.
Interim snapshot and trailing twelve months: notes and sources
Source: 1H2026 results. TTM equals FY2025 minus 1H2025 plus 1H2026. Excluding share-based payments, the 1H2026 loss for the period would have been roughly S$0.4 million (analyst calculation). Non-controlling interests earned a profit of S$732k in 1H2026, consistent with profitable activity inside the newly formed 51%-owned Jinhai Biomedical.
Balance sheet
At 30 June 2026 (1H2026 results):
-
Total assets S$100.3m; bank and cash S$18.2m plus time deposits S$10.5m (S$28.7m in total).
-
Trade receivables S$25.9m; trade payables S$23.4m; inventories S$3.3m.
-
Borrowings S$11.9m; lease liabilities S$2.3m.
-
Total equity S$55.7m, of which non-controlling interests S$3.8m; net current assets S$31.0m.
-
New items: a S$2.85m prepayment for PPE and a S$3.6m prepayment to a contractor, which point to a capital project. Its nature is not disclosed.
FY2022 cash excludes a S$968k fixed deposit. FY2023 goodwill is shown as 0 because no goodwill line appeared on the FY2023 balance sheet, while goodwill of S$522k is carried from FY2024.
Cash flow
The company disclosed FY2025 PPE capex of S$0.1m (FY2024: S$1.0m) and gross equity proceeds of S$26.6m from the August 2025 subscription, and stated no buybacks in any period. FY2023 financing inflow reflects the October 2023 placing (S$17.47m gross).
Ratios
Notes: Debt/equity matches the company's reported gearing ratio for FY2021–FY2025. Net debt/EBITDA for FY2024 and FY2025 is mechanically computed but not meaningful because EBITDA was negative. Receivable and payable days use year-end balances against revenue and cost of sales. Inventory days use cost of inventories sold where disclosed (FY2023–FY2025) and cost of sales otherwise.
Commentary on trends, inflections and drivers
Revenue. The five-year record has three phases. FY2021–FY2022 was a COVID-depressed Singapore services business at roughly S$22m. FY2023 saw revenue double to S$45.6m as the PRC medical business scaled to S$20.4m and dormitory rents surged. FY2024–FY2025 brought a plateau and then a decline at group level (S$50.2m, then S$46.3m) as Singapore dormitory income collapsed, partly masking continued medical growth (+26.9%, then +15.6%). The 1H2026 print of S$34.0m, up 134% YoY, is the first clear sign that medical growth now dominates the group trajectory. TTM revenue reached a record S$65.8m.
Gross margin. The steady compression from 45.4% (FY2022) to 15.5% (FY2025) is a mix effect. High-margin rental and labour revenue was replaced by low-margin product sales, and the FY2023 MD&A explicitly cites the low margin of the MIS business. The partial recovery to 19.5% in 1H2026 coincides with better implied product margins (about 15% vs about 5% in FY2023–FY2024) and a rebound in Singapore dormitory rental rates.
Operating losses. The FY2024–FY2025 losses (about S$18m and S$17m) are heavily distorted by non-cash share-based payments of S$13.2m and S$9.1m from the January 2024 option grant. Underlying EBITDA excluding these charges was approximately break-even in FY2024 (+S$0.7m) and modestly negative in FY2025 (−S$2.8m). The FY2023 admin step-up (+S$5.7m) reflected promotional and marketing spend, hiring of industry veterans and leased R&D space for the medical business.
Balance sheet. The group was net cash in four of five year-ends. Equity has been replenished twice by placements to insiders and associates: S$17.5m in October 2023 and S$26.6m in August 2025. These placements, not internal cash generation, have funded accumulated losses. Borrowings (S$12.0m at end-FY2025) are short-term, secured on the Singapore dormitories, and partly comprise loans from the parent company for daily operations (FY2025 MD&A). The group reported no unutilised banking facilities at end-FY2025 or at 30 June 2026.
Working capital. The jump in receivable days to 121 at end-FY2025 and payables to 153 days reflects large, back-end-loaded product sales to concentrated customers, financed by extended supplier credit. Trade payables over 90 days rose from S$0.1m (FY2024) to S$5.9m (FY2025) and S$8.0m (1H2026). This is a key monitorable for cash-flow quality.
Returns. ROE, ROA and ROIC have been negative since FY2023 and are unlikely to turn positive before share-based payment charges taper. The third and largest option tranche (50%) vests on 30 April 2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Products revenue (SGD K) | 1,558 | 656 | 20,431 | 25,927 | 29,964 |
Services revenue (SGD K) | 20,338 | 21,624 | 25,213 | 24,314 | 16,312 |
Total revenue (SGD K) | 21,896 | 22,280 | 45,644 | 50,241 | 46,276 |
Products profit before tax (SGD K) | -754 | -704 | -2,178 | -3,645 | -2,088 |
Services profit before tax (SGD K) | 2,817 | 3,916 | 1,912 | 1,700 | -3,514 |
Others/corporate profit before tax (SGD K) | -2,126 | -2,428 | -2,951 | -16,282 | -11,560 |
Group profit before tax (SGD K) | -62 | 784 | -3,217 | -18,227 | -17,162 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Products PBT margin (%) | -48.4 | -107.3 | -10.7 | -14.1 | -7.0 |
Services PBT margin (%) | 13.9 | 18.1 | 7.6 | 7.0 | -21.5 |
Products revenue YoY growth (%) | 0 | -57.9 | 3,014.5 | 26.9 | 15.6 |
Services revenue YoY growth (%) | 0 | 6.3 | 16.6 | -3.6 | -32.9 |
Products share of group revenue (%) | 7.1 | 2.9 | 44.8 | 51.6 | 64.7 |
Services share of group revenue (%) | 92.9 | 97.1 | 55.2 | 48.4 | 35.3 |
Business Lines
| Business line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
MIS solutions and medical products and service fee (SGD K) | 1,558 | 656 | 20,431 | 25,927 | 29,964 |
Manpower outsourcing and ancillary services (SGD K) | 14,307 | 15,018 | 15,750 | 15,116 | 12,685 |
Dormitory services (SGD K) | 4,789 | 5,787 | 8,615 | 8,419 | 2,923 |
IT services (SGD K) | 567 | 417 | 476 | 500 | 434 |
Construction ancillary services (SGD K) | 674 | 402 | 372 | 279 | 270 |
Business line YoY growth (%)
| Business line YoY growth (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
MIS and medical products YoY (%) | -57.9 | 3,016.6 | 26.9 | 15.6 |
Manpower outsourcing YoY (%) | 5.0 | 4.9 | -4.0 | -16.1 |
Dormitory services YoY (%) | 20.8 | 48.9 | -2.3 | -65.3 |
IT services YoY (%) | -26.4 | 14.1 | 5.0 | -13.2 |
Construction ancillary YoY (%) | -40.4 | -7.5 | -25.0 | -3.2 |
Revenue by Segment
| Metric | 1H2024 | 2H2024 | 1H2025 | 2H2025 | 1H2026 |
|---|---|---|---|---|---|
MIS and medical products revenue (SGD K) | 12,302 | 13,625 | 6,333 | 23,631 | 25,427 |
Manpower outsourcing revenue (SGD K) | 0 | 0 | 6,451 | 6,234 | 6,372 |
Dormitory revenue (SGD K) | 0 | 0 | 1,378 | 1,545 | 1,909 |
Group revenue (SGD K) | 25,937 | 24,304 | 14,529 | 31,747 | 34,021 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (SGD K) | 21,896 | 22,280 | 45,644 | 50,241 | 46,276 |
Cost of sales and services (SGD K) | 14,169 | 12,164 | 33,615 | 38,764 | 39,087 |
Gross profit (SGD K) | 7,727 | 10,116 | 12,029 | 11,477 | 7,189 |
Administrative expenses (SGD K) | 8,697 | 10,242 | 15,941 | 31,942 | 24,463 |
of which equity-settled share-based payments (SGD K) | 0 | 0 | 0 | 13,152 | 9,119 |
Depreciation, all categories (SGD K) | 5,365 | 4,387 | 4,102 | 5,019 | 4,618 |
EBIT (SGD K) | 70 | 869 | -2,996 | -17,454 | -16,487 |
EBITDA (SGD K) | 5,435 | 5,256 | 1,106 | -12,435 | -11,869 |
EBITDA excluding share-based payments (SGD K) | 5,435 | 5,256 | 1,106 | 717 | -2,750 |
Finance costs (SGD K) | 132 | 85 | 221 | 773 | 675 |
Profit before tax (SGD K) | -62 | 784 | -3,217 | -18,227 | -17,162 |
Income tax expense (SGD K) | 435 | 668 | 895 | 28 | 233 |
Net income, total (SGD K) | -498 | 116 | -4,112 | -18,255 | -17,395 |
Net income attributable to owners (SGD K) | -246 | 468 | -3,141 | -17,965 | -17,080 |
Basic and diluted EPS as reported (S$ cents) | -0.02 | 0.04 | -0.25 | -0.35 | -0.33 |
Basic EPS adjusted for Dec 2024 1:4 subdivision (S$ cents) | -0.005 | 0.010 | -0.063 | -0.35 | -0.33 |
Dividends per share (S$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 35.3 | 45.4 | 26.4 | 22.8 | 15.5 |
EBIT margin (%) | 0.3 | 3.9 | -6.6 | -34.7 | -35.6 |
EBITDA margin (%) | 24.8 | 23.6 | 2.4 | -24.8 | -25.6 |
Net margin, total (%) | -2.3 | 0.5 | -9.0 | -36.3 | -37.6 |
Revenue YoY growth (%) | -2.6 | 1.8 | 104.9 | 10.1 | -7.9 |
Margin Analysis (%) and Per-Share Data
| Metric | 1H2025 | 1H2026 | TTM to Jun 2026 |
|---|---|---|---|
Revenue | 14,529 | 34,021 | 65,768 |
Gross profit | 2,082 | 6,622 | 11,729 |
Gross margin (%) | 14.3 | 19.5 | 17.8 |
Administrative expenses | 12,505 | 9,959 | 21,917 |
Share-based payments | 5,270 | 3,230 | 7,079 |
Loss before tax | -10,722 | -2,997 | -9,437 |
Loss for the period | -10,800 | -3,630 | -10,225 |
Loss attributable to owners | -10,253 | -4,362 | -11,189 |
Basic loss per share (S$ cents) | -0.20 | -0.08 | — |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (SGD K) | 33,769 | 40,272 | 62,220 | 58,867 | 88,834 |
Cash and bank balances (SGD K) | 16,257 | 15,385 | 20,196 | 10,446 | 35,588 |
Investment properties (SGD K) | 1,009 | 1,082 | 12,512 | 21,308 | 18,753 |
Inventories (SGD K) | 874 | 959 | 2,097 | 2,769 | 3,004 |
Trade receivables (SGD K) | 1,465 | 2,212 | 5,531 | 4,856 | 15,384 |
Listed investments at FVTPL (SGD K) | 8,736 | 7,592 | 6,564 | 4,479 | 1,193 |
Short-term debt incl. current leases (SGD K) | 1,614 | 2,768 | 6,603 | 11,791 | 13,051 |
Long-term debt incl. non-current leases (SGD K) | 254 | 1,681 | 3,478 | 2,731 | 1,857 |
Total debt incl. leases (SGD K) | 1,868 | 4,450 | 10,081 | 14,522 | 14,908 |
Net debt (debt minus cash; negative = net cash) (SGD K) | -14,389 | -10,935 | -10,115 | 4,076 | -20,680 |
Total equity (SGD K) | 24,024 | 24,592 | 37,490 | 32,779 | 51,962 |
Equity attributable to owners (SGD K) | 24,275 | 24,368 | 37,474 | 31,806 | 51,288 |
Goodwill and intangibles (SGD K) | 0 | 0 | 0 | 522 | 522 |
Working capital (net current assets) (SGD K) | 21,242 | 19,303 | 21,430 | 6,807 | 29,419 |
Trade payables (SGD K) | 264 | 477 | 5,462 | 5,129 | 16,400 |
Cash Flow
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Operating cash flow (SGD Mn) | 7.38 | 3.34 | 4.24 | -1.91 | -3.25 |
Capital expenditure, implied (SGD Mn) | 0.13 | 0.61 | 1.18 | 1.24 | 1.01 |
Free cash flow (SGD Mn) | 7.25 | 2.73 | 3.06 | -3.15 | -4.26 |
Investing cash flow (SGD Mn) | -6.04 | -2.64 | -1.15 | -6.51 | -9.22 |
Financing cash flow (SGD Mn) | -4.15 | -4.81 | -3.72 | 13.62 | 2.93 |
Dividends paid (SGD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (SGD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable NI / average attributable equity (%) | -1.0 | 1.9 | -10.2 | -51.9 | -41.1 |
ROA, total NI / average total assets (%) | -1.4 | 0.3 | -8.0 | -30.2 | -23.6 |
ROIC, after-tax EBIT / (equity + debt − cash) (%) | -3.8 | 1.5 | -14.2 | -47.4 | -52.7 |
Current ratio (x) | 3.24 | 2.38 | 2.01 | 1.29 | 1.84 |
Debt (incl. leases) / equity (%) | 7.8 | 18.1 | 26.9 | 44.3 | 28.7 |
Net debt / EBITDA (x; not meaningful when EBITDA ≤ 0) | -2.65 | -2.08 | -9.15 | -0.33 | 1.74 |
Interest coverage, EBIT / finance costs (x) | 0.5 | 10.2 | -13.6 | -22.6 | -24.4 |
Asset turnover (x) | 0.60 | 0.60 | 0.89 | 0.83 | 0.63 |
Receivable days | 24 | 36 | 44 | 35 | 121 |
Inventory days | 23 | 29 | 39 | 41 | 42 |
Payable days | 7 | 14 | 59 | 48 | 153 |
Cash conversion cycle (days) | 40 | 51 | 24 | 28 | 10 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
PRC / Mainland China revenue (SGD K) | 1,558 | 656 | 20,431 | 25,927 | 29,989 |
Singapore revenue incl. dormitory rental (SGD K) | 20,338 | 21,624 | 25,213 | 24,314 | 16,287 |
Total (SGD K) | 21,896 | 22,280 | 45,644 | 50,241 | 46,276 |
Region growth and share (%)
| Region growth and share (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
PRC YoY growth (%) | -57.9 | 3,014.5 | 26.9 | 15.7 |
Singapore YoY growth (%) | 6.3 | 16.6 | -3.6 | -33.0 |
PRC share of revenue (%) | 2.9 | 44.8 | 51.6 | 64.8 |
Singapore share of revenue (%) | 97.1 | 55.2 | 48.4 | 35.2 |
Segment Overview
| Segment | PRC | Singapore | Hong Kong | Total |
|---|---|---|---|---|
Products (MIS and medical) | 29,964 | 0 | 0 | 29,964 |
Services (manpower, IT, construction ancillary) | 25 | 13,364 | 0 | 13,389 |
Dormitory rental | 0 | 2,923 | 0 | 2,923 |
Total | 29,989 | 16,287 | 0 | 46,276 |
Locations
| Location | FY2022 | FY2023 | FY2025 | 30 Jun 2026 |
|---|---|---|---|---|
Singapore (SGD K) | 1,282 | 13,387 | 19,640 | 19,324 |
Mainland China (SGD K) | 5,059 | 4,192 | 3,065 | 5,416 |
Hong Kong (SGD K) | 468 | 1,362 | 1,146 | 840 |
Share Price
| Metric | Oct2017 | Jul2019 | Mar2021 | Jul2021 | Sep2023 | Jan2024 | Jul2025 | Apr2026 | Jun2026 | Aug2026 | Oct2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Split-adjusted share price (HKD) | 0.130 | 0.102 | 0.383 | 0.785 | 0.498 | 0.635 | 1.640 | 4.530 | 3.330 | 4.935 | 4.250 |
Margin Analysis (%) (Approx. 5-year (vs Jul 2021)–Approx. 1-year (vs Jul 2025))
| Metric | Approx. 1-year (vs Jul 2025) | Approx. 3-year (vs Sep 2023) | Approx. 5-year (vs Jul 2021) |
|---|---|---|---|
Share price change (%) | 159 | 754 | 441 |
Valuation Snapshot
| Metric | Value |
|---|---|
Market capitalisation (HKD Mn) | 22,521 |
Market capitalisation (SGD Mn) | 3,702 |
Enterprise value (SGD Mn), market cap + debt S$14.2m − cash and deposits S$28.7m | 3,688 |
TTM revenue to Jun 2026 (SGD Mn) | 65.8 |
EV / TTM sales (x) | 56.1 |
Price / book, equity attributable at 30 Jun 2026 of S$52.0m (x) | 71.2 |
P/E (x) | Not meaningful (loss-making) |
EV / EBITDA (x) | Not meaningful (negative EBITDA) |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | No identifiable broker coverage. TipRanks displayed a single "Hold" rating with a HK$0.50 target in mid-2025; source and methodology unclear, so low reliability |
Dividend history | No dividends declared or paid FY2021–1H2026; no fixed payout ratio. Board cites losses and cash retention (AR2025 dividend policy) |
Buybacks | None executed. AGM (15 Jun 2026) granted a 10% repurchase mandate (about 529m shares) |
Issue mandate | 20% general mandate (about 1.06bn shares) |
Credit ratings (Moody's / S&P / Fitch) | None; unrated |
Debt maturity profile at 30 Jun 2026 | Borrowings S$11.9m, all current and secured on Singapore investment properties (S$18.2m); lease liabilities S$0.9m current and S$1.4m non-current; no unutilised bank facilities |
Analyst Conclusions
Management guidance
There are no numerical targets. Management:
-
Expects medical sales to continue to grow in 2H2026 and is prepared to expand medical product operations in China.
-
Will review the Singapore manpower business in 2H2026.
-
Expects 2H2026 to be economically challenging and continues stringent cost controls.
-
Intends to deploy the HK$146.3m of unutilised August 2025 proceeds (M&A, R&D, working capital) by the end of December 2026.
(1H2026 results.)
Consensus
No formal consensus exists. The only visible third-party commentary is supportive financial media (Zhitong Finance) on profit recovery and import substitution, which should not be treated as independent research.
Bull case
-
Medical inflection is real. Medical revenue rose 301.5% to S$25.4m in 1H2026, the TTM group run-rate is S$65.8m, and ex-SBP losses are near zero. If 2H2026 matches 1H2026, FY2026 medical revenue could exceed S$50m and deliver a first operating profit once share-based payments taper after April 2027.
-
Medtronic validation plus a war chest. The co-launched navigated spinal endoscopy technique and framework agreement, together with about HK$82m of M&A proceeds, could produce an acquisition that adds proprietary products and higher margins.
-
Simplification optionality. A sale or wind-down of Singapore manpower and dormitories could release capital (dormitory book value S$18.2m), remove a shrinking, policy-exposed segment and leave a pure-play medical story.
Bear case
-
Concentration and quality of revenue. Two customers supplied 98% of 1H2026 product revenue, implied product margins are about 12–15%, and receivables and supplier credit have ballooned. That profile resembles low-value trading more than a defensible device franchise.
-
Valuation detached from fundamentals. About 56x EV/sales and 71x P/B for a company with S$52m of equity and a record of losses, a 2021 SFC concentration warning, and an 8.4% overhang of deep-in-the-money options plus a 20% issue mandate leave substantial downside risk.
-
Governance and related-party risk. The controlling shareholder holds about 47.7%. A new subsidiary is 49% owned by the Co-chairman's children, the group borrows from its parent, five directors have left since January 2025, and the CPA-qualified INED resigned in September 2026.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| FY2026 annual results | Approx. late March 2027 | Medical revenue above S$50m? Gross margin above 20%? Operating cash flow positive? |
| Deployment of Aug 2025 proceeds | By Dec 2026 | Identity, price and related-party nature of any healthcare acquisition |
| Singapore business review | 2H2026 | Disposal, closure or restructuring of manpower and dormitories |
| Customer A and B disclosures | Each results release | Whether concentration eases and new customers emerge |
| Medtronic collaboration | Ongoing | Definitive commercial agreements, procedure volumes, NMPA registrations |
| Option vesting and exercise | Third tranche 30 Apr 2027 | Dilution and selling pressure; SBP charge roll-off |
| Board composition | Ongoing | Audit committee accounting expertise after Ms. Yang's exit; further turnover |
| Working capital | Interim and annual | Receivable days, payables over 90 days, parent-company loans |
| Use of issue mandate | Ongoing | Further discounted placements |
Concluding analyst verdict
Jinhai Medical Technology is two very different companies inside one listed shell. One is a declining Singapore labour and dormitory operator whose revenue has fallen to S$16m and which management itself expects to be hurt by Singapore's AI-centric fiscal priorities. The other is a fast-growing Shanghai medical-products business, now three-quarters of revenue, that delivered S$25.4m of sales in the first half of 2026 alone and pulled group losses to near break-even before non-cash option costs. The Medtronic collaboration in navigated spinal endoscopy is the most credible piece of external validation the group has produced. Fresh insider capital provides runway, and the group holds about S$29m in cash and deposits against S$14m of secured debt.
The evidence does not yet support the thesis that Jinhai has built a defensible medical-technology franchise. Disclosed R&D is below 2% of revenue. Implied product margins sit in the low teens. Almost all product revenue comes from two undisclosed customers. Working capital is being financed by stretched supplier credit and parent loans. Governance is dominated by the controlling shareholder and a new co-chairman whose family co-owns the newest operating subsidiary. Board turnover has been unusually high.
Against these fundamentals, a market value of roughly HK$22.5 billion, about 56 times trailing sales and over 70 times book, prices in an outcome far beyond anything the filings demonstrate. Historical episodes of extreme shareholding concentration and the large overhang of deep-in-the-money options and issuance mandates add technical risk.
The verdict is that operating momentum is improving and genuine, but the investment case is speculative and valuation-driven. Institutional investors should treat the stock as high-risk. Re-underwriting should be conditional on three things: diversification of the customer base, disclosure of proprietary products and registrations, and the terms of the forthcoming healthcare acquisition funded by the August 2025 proceeds.
APPENDIX: SOURCES
Primary filings (HKEX):
-
FY2022 annual results announcement, 30 Mar 2023: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0331/2023033100055.pdf
-
Annual Report 2022: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0428/2023042800657.pdf
-
Annual Report 2021: https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0429/2022042900416.pdf
-
Interim Report 2023: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0925/2023092500193.pdf
-
Subscription completion, Oct 2023: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1018/2023101800175.pdf
-
FY2023 annual results announcement, 27 Mar 2024: https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0328/2024032800013.pdf
-
1H2024 interim results: https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0830/2024083001304.pdf
-
Appointment and resignation of directors, 28 Jan 2025: https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0128/2025012800216.pdf
-
Profit warning, 26 Aug 2025: https://www.hkexnews.hk/listedco/listconews/sehk/2025/0826/2025082600695_c.pdf
-
1H2025 interim results: https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0829/2025082901245.pdf
-
Interim Report 2025: https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0923/2025092300256.pdf
-
FY2025 annual results announcement, 27 Mar 2026: https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0327/2026032704510.pdf
-
Annual Report 2025: https://www.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400802.pdf
-
1H2026 interim results, 27 Aug 2026: https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0827/2026082700356.pdf
-
CMO appointment, 3 Aug 2026: https://pdf.dfcfw.com/pdf/H2_AN202608031827591071_1.pdf
-
Director changes, 18 Sep 2026: https://pdf.dfcfw.com/pdf/H2_AN202609181829616678_1.pdf
-
SFC shareholding concentration response, Jul 2021: https://newsfile.moomoo.com/notice/2021/07/29/9869979-0.PDF
-
Discloseable transactions, Dec 2021: https://www.hkexnews.hk/listedco/listconews/sehk/2021/1210/2021121000415.pdf
-
Kakiko / Full Fortune offer, May 2019: https://www1.hkexnews.hk/listedco/listconews/sehk/2019/0531/ltn201905311158.pdf
-
Offer close, Jul 2019: https://www1.hkexnews.hk/listedco/listconews/sehk/2019/0719/ltn20190719673.pdf
-
IPO offer price announcement, Oct 2017: https://www1.hkexnews.hk/listedco/listconews/sehk/2017/1004/ltn20171004015.pdf
Aggregators and media (flagged where used):
-
etnet announcements and quote: https://www.etnet.com.hk/www/tc/stocks/realtime/quote_announcement.php?code=2225
-
TipRanks income statement: https://www.tipranks.com/stocks/hk:2225/financials/income-statement
-
TipRanks cash flow: https://www.tipranks.com/stocks/hk:2225/financials/cash-flow
-
TipRanks revenue history: https://www.tipranks.com/stocks/hk:2225/revenue
-
TipRanks 1H2025 note: https://www.tipranks.com/news/company-announcements/jinhai-medical-technology-reports-decline-in-1h2025-financial-results
-
TipRanks AGM note: https://www.tipranks.com/news/company-announcements/jinhai-medical-technology-announces-2025-annual-general-meeting
-
Stoxray profile: https://stoxray.com/stocks/xhkg/2225
-
FilingReader 1H2025 summary: https://filingreader.com/news-wire/hongkong/2025-09-23/jinhai-medical-technology-reports-revenue-decline-wider-loss-in-1h-2025
-
Zhitong / Webull commentary on 1H2026: https://www.webull.com/news/15485898856539136
-
Tiger Brokers bulletin, Li Bin appointment: https://www.itiger.com/news/1131986474
-
Tiger Brokers bulletin, Jiang Jiangyu resignation: https://www.itiger.com/news/1141058779
-
Tiger Brokers bulletin, 2026 AGM circular: https://www.itiger.com/news/1124627705
-
MarketScreener, company secretary change: https://uk.marketscreener.com/news/jinhai-medical-technology-limited-announces-change-of-company-secretary-effective-september-29-202-ce7d5bdcd88df221
-
MarketScreener, Li Bin appointment: https://uk.marketscreener.com/news/jinhai-medical-technology-limited-appoints-li-bin-as-executive-director-and-co-chairman-effective-f-ce7e5adede80f022
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed | Age (AR2025) | Prior roles / background | Education |
|---|---|---|---|---|---|
Chen Guobao (陳國寶) | Chairman, Executive Director, Chair of Nomination Committee; controlling shareholder | 19 Jul 2019 | 51 | About 20 years in real estate and construction. Founded Shanghai Jinhai Corporate Development Group (2002; real estate development and property management incl. dormitories). Chairman of Shanghai Guobao Property (since 2006) and Shanghai Laiyada Property Development (since 2011). Executive deputy chairman, Ningbo Chamber of Commerce in Shanghai. Former NED of Vision Fame International (1315.HK), 2015–2017 | Undergraduate studies in economic management, PLA Nanjing Artillery Academy (completed 2012) |
Li Bin (李斌) | Co-chairman, Executive Director | 3 Feb 2026 | 53 | Founder and chairman of Shanghai Anbaida Investment Management Consulting (IVD reagent sales) since 2005; first-tier Roche Diagnostics distributor in Shanghai since 2004; senior management consultant to Jin Hai Holdings (HK) (Chen-owned), Sep 2025–Feb 2026 | — |
Wang Zhenfei (王振飛) | Chief Executive Officer, Executive Director, Remuneration Committee member | 19 Jul 2019 | 45 | Huaxia Bank Shanghai Branch, 2007–2015; CEO of Shanghai Jinhai Corporate Development Group since 2015 | Business management (online distance learning), Southwest University of Science and Technology, 2007 |
Wang Huasheng (王華生) | Non-executive Director, Audit Committee member | 19 Jul 2019 | 60 | Founder and chairman of Shaanxi Yide Industrial (2004), Shaanxi Northwest Light Industry Wholesale Market Management (2006), Shanghai Gexin Investment (2007) and Shanghai Gexin Real Estate (2009) | — |
Yan Jianjun (嚴健軍) | INED; Chair of Audit and Remuneration Committees; Nomination Committee member | 19 Jul 2019 | 60 | Chairman, Shanghai Zhida Technology Group (since 1999). Independent director of Dazhong Transportation (600611.SS) since 2024; INED of Butong Group (6090.HK) since Sep 2025; formerly independent director of Shanghai Lonyer Fuels (603003.SH). Shanghai People's Congress deputy; National Model Worker | BEng (electrical engineering), Shanghai University of Engineering Science; EMBA, CEIBS (2003) |
Fan Yimin (范一民) | INED; Audit, Remuneration and Nomination Committee member | 19 Jul 2019 | 43 | Bank of China Shanghai (2005–2012); Shanghai Stem Cell Technology (2012–2015); Shanghai Zhengming Modern Logistics (2016–2017); KEB Hana Bank (China) Shanghai, assistant GM, corporate division (since 2018) | Bachelor's in finance, Donghua University (2005) |
Liu Jinjing (劉金晶) | INED; Audit and Nomination Committee member | 18 Sep 2026 | — | — | — |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Since | Notes |
|---|---|---|---|
Wang Zhenfei | CEO | Jul 2019 | See above; holds 25.85m options at HK$0.635 (post-subdivision) |
Liu Lei (劉鐳) | Chief Technical Officer; director and GM of Shanghai Jinhai Medical | — | Largest option holder: 284.35m options outstanding at 30 Jun 2026, about 5.4% of issued shares |
Wong Man Yiu (黃文耀) | CFO (rejoined 1 Sep 2025); Company Secretary and Authorised Representative (29 Sep 2025) | 2025 (previously 2019–2023) | Aged 58; HKICPA associate (1996), ACCA fellow (2001) |
Ma Chengdong (馬成棟) | Chief Marketing Officer | 3 Aug 2026 (initial 1-year term) | Oversees marketing, market access, academic promotion, sales and channels for medical devices |
“—” = not publicly disclosed.
Executive Leadership Team by Person
| Person | Component | Amount | Source |
|---|---|---|---|
Li Bin | Fixed director's fee | HK$200,000 per month (HK$2.4m annualised); 3-year service contract | Appointment announcement, 3 Feb 2026 |
Jiang Jiangyu (former) | Director's fee | HK$504,000 per annum | Appointment announcement, 28 Jan 2025 |
Senior management (per AR2025 band table) | Total remuneration | 2 individuals HK$500,001–1,500,000; 2 individuals HK$3,500,001–4,000,000 | AR2025 CG Report |
Individual directors' salary/bonus/share-based totals | FY2025 | — | AR2025 |
Group staff costs incl. directors | FY2025 | S$22.5m (incl. S$9.1m share-based payments); FY2024 S$30.5m | FY2025 results |
Major Shareholders
| Holder | Shares | % of issued shares | Date / source |
|---|---|---|---|
Full Fortune International Co., Ltd (100% Chen Guobao; spouse Jiang Xiahong deemed interested) | 2,530,000,000 | 47.82 (approx. 47.74 on 5,299m shares at 30 Jun 2026) | AR2025 (31 Dec 2025) |
Li Bin (Co-chairman) | 40,000,000 | approx. 0.75 | Appointment announcement, Feb 2026 |
Li Yue and Li Zekai (Li Bin's children), combined | — | approx. 1.51 | Derived from 120m August 2025 subscription |
Option holders (Liu Lei 284.35m; Wang Zhenfei 25.85m; four employees 135.76m) | 445,960,000 options outstanding | approx. 8.4 potential dilution | 1H2026 results |
Institutional investors (top 10) | Not publicly disclosed (none above the 5% SFO threshold reported) | — | AR2025 Section 336 register |
Public float | Approx. 50% by arithmetic; the company confirmed sufficient public float throughout FY2025 and 1H2026 | — | Results announcements |
Competitive Landscape
Key Competitors
| Competitor | Listing | Relevance | Relative positioning vs Jinhai |
|---|---|---|---|
Medtronic plc | NYSE: MDT | Global leader in spine, navigation and neurosurgery; Jinhai's partner in navigated spinal endoscopy | Orders of magnitude larger (FY ended April 2025 revenue approx. US$33.5bn); simultaneously partner and potential competitor |
Johnson & Johnson MedTech (DePuy Synthes) | NYSE: JNJ | Spine, orthopaedics and endoscopy | Global scale; competes in hospital spine procurement |
Stryker | NYSE: SYK | Spine, navigation and endoscopy | Global scale |
Olympus | TSE: 7733 | Endoscopy systems | Global leader in visualisation |
Karl Storz | Private | Endoscopy and MIS visualisation | Global leader; private |
MicroPort Scientific | HKEX: 0853 | Diversified Chinese device maker incl. orthopaedics | Far larger, vertically integrated |
MicroPort MedBot | HKEX: 2252 | Surgical robotics incl. orthopaedic and endoscopic robots | R&D-intensive robotics platform |
Kangji Medical | HKEX: 9997 | Chinese MIS instruments (laparoscopic) | Profitable domestic MIS specialist |
Shandong Weigao Group Medical Polymer | HKEX: 1066 | Broad consumables incl. orthopaedics | Large, diversified |
Shanghai Sanyou Medical | SSE: 688085 | Domestic spine implants | Spine specialist |
Weigao Orthopaedic | SSE: 688161 | Domestic orthopaedic and spine implants | Spine specialist |
Joimax | Private (Germany) | Spinal endoscopy and navigation systems | Niche global spinal endoscopy specialist |
Key Competitors — Centurion Corporation
| Competitor | Listing | Relevance |
|---|---|---|
Centurion Corporation | SGX: OU8 | Purpose-built workers' accommodation operator in Singapore and Malaysia |
Numerous private foreign-worker agencies and labour suppliers | Private | Fragmented, licence-based Singapore manpower supply |
Peer Comparison FY2025
| Metric | Jinhai (FY2025) | Medtronic |
|---|---|---|
Revenue | S$46.3m group; S$30.0m medical | Approx. US$33.5bn (FY Apr 2025) |
Revenue growth | −7.9% group; +15.6% medical; +301.5% medical in 1H2026 | — |
Gross margin | 15.5% group; approx. 12.7% implied on products | — |
Operating margin | −35.6% (EBIT) | — |
R&D intensity | 1.6% of revenue | — |
Business model | Distributor and solution provider with concentrated customers | Global OEM |
Recent Developments
Headcount declined modestly from 488 to 472 between end-2024 and mid-2026.



